

Don't settle for just a supplier. Find a custom manufacturing partner.

Your specifications. Your format.
Our scientists waiting to help.



Let's **TALK**
CUSTOM



Selecting a supplier for your clinical/diagnostic products can be a challenge—especially a supplier who can adapt to your specific needs. Don't settle for just a supplier. Instead, partner with Promega and work with a custom manufacturer willing to provide you with the scientific expertise, ongoing technical support and quality standards that support your success.



Learn more with our free webinar:
promega.com/CustomWebinar

Autosomal recessive primary microcephaly due to *ASPM* mutations: An update

Pascaline Létard^{1,2,3} | Séverine Drunat^{1,4} | Yoann Vial^{1,4} | Sarah Duerinckx⁵ |
 Anais Ernault⁴ | Daniel Amram⁶ | Stéphanie Arpin⁷ | Marta Bertoli⁸ |
 Tiffany Busa⁹ | Berten Ceulemans¹⁰ | Julie Desir⁵ | Martine Doco-Fenzy¹¹ |
 Siham Chafai Elalaoui^{12,13} | Koenraad Devriendt¹⁴ | Laurence Faivre¹⁵ |
 Christine Francannet¹⁶ | David Geneviève¹⁷ | Marion Gérard¹⁸ | Cyril Gitiaux¹⁹ |
 Sophie Julia²⁰ | Sébastien Lebon²¹ | Toni Lubala²² | Michèle Mathieu-Dramard²³ |
 Hélène Maurey²⁴ | Julia Metreau²⁴ | Sanaa Nasserereddine²⁵ | Mathilde Nizon²⁶ |
 Geneviève Pierquin²⁷ | Nathalie Pouvreau^{1,4} | Clothilde Rivier-Ringenbach²⁸ |
 Massimiliano Rossi^{29,30} | Elise Schaefer³¹ | Abdelaziz Sefiani^{12,13} | Sabine Sigaudy⁹ |
 Yves Sznajer³² | Yusuf Tunca³³ | Sophie Guilmin Crepon^{34,35} | Corinne Alberti^{34,35} |
 Monique Elmaleh-Bergès³⁶ | Brigitte Benzacken^{1,3,37} | Bernd Wollnick³⁸ |
 C. Geoffrey Woods³⁹ | Anita Rauch⁴⁰ | Marc Abramowicz⁵ | Vincent El Ghouzzi¹ |
 Pierre Gressens^{1,41,42} | Alain Verloes^{1,4} | Sandrine Passemard^{1,4,42} 

¹PROTECT, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France²Service d'Anatomie et de cytologie pathologiques, Hôpital Universitaire Jean Verdier, APHP, Bondy, France³Université Paris 13, Sorbonne Paris Cité, UFR de Santé, Médecine et Biologie Humaine, Bobigny, France⁴Département de Génétique, Hôpital Universitaire Robert Debré, APHP, Paris, France⁵Department of Medical Genetics, Hôpital Erasme and IRIBHM, Université Libre de Bruxelles, Brussels, Belgium⁶Unité de Génétique Clinique, Centre Hospitalier Intercommunal de Créteil, Créteil, France⁷Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Tours, Tours, France⁸Northern Genetics Service, Newcastle upon Tyne NHS Trust, Newcastle upon Tyne, UK⁹Service de Génétique Clinique, AP-HM, Hôpital Universitaire Timone Enfants, Marseille, France¹⁰Department of Pediatric Neurology, University Hospital and University of Antwerp, Antwerp, Belgium¹¹Service de Génétique, Centre Hospitalier Universitaire de Reims, Hôpital Maison blanche, et EA3801 SFR CAPSANTÉ, Reims, France¹²Centre de Génomique Humaine, Faculté de médecine et de Pharmacie de Rabat, Université Mohamed V, Rabat, Morocco¹³Département de Génétique Médicale, Institut National d'Hygiène, Rabat, Morocco¹⁴Center for Human Genetics, University of Leuven, Leuven, Belgium¹⁵Service de Génétique Médicale et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France¹⁶Service de Génétique Médicale, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France¹⁷Département de Génétique Médicale, Maladies rares et Médecine Personnalisée, Centre Hospitalier Universitaire de Montpellier, Montpellier, France¹⁸Service de Génétique Clinique, Centre Hospitalier Universitaire de Caen, Caen, France¹⁹Département de neurologie pédiatrique, Hôpital Universitaire Necker Enfants Malades, APHP, Paris, France²⁰Service de génétique médicale, Centre Hospitalier Universitaire de Toulouse, Toulouse, France²¹Unité de neuropédiatrie et neuroréhabilitation pédiatrique, Département Femme Mère Enfant, Lausanne University Hospital (CHUV), Lausanne, Switzerland²²Department of Pediatrics, Sendwe University Hospitals, University of Lubumbashi, Lubumbashi, DR Congo

- ²³Centre d'Activité Génétique Clinique et Oncogénétique, Centre Hospitalier Universitaire d'Amiens, Amiens, France
- ²⁴Service de neurologie pédiatrique, Hôpital Universitaire Bicêtre, Le Kremlin-Bicêtre, APHP, France
- ²⁵Laboratoire de génétique et pathologie moléculaire, Centre Hospitalier Universitaire Ibn Rochd, Casablanca, Morocco
- ²⁶Département de Génétique, Centre Hospitalier Universitaire de Nantes, Nantes, France
- ²⁷Département de Génétique, Centre Hospitalier Universitaire de Liège, Liège, Belgique
- ²⁸Service de pédiatrie, Hôpital Nord Ouest-Villefranche, Gleize, France
- ²⁹Département de Génétique, Hospices Civils de Lyon, Lyon, France
- ³⁰INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon, GENDEV Team, Université Claude Bernard Lyon 1, Bron, France
- ³¹Service de Génétique Médicale, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France
- ³²Centre for Human Genetics, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
- ³³Department of Medical Genetics, Gulhane School of Medicine, Gulhane Training and Research Hospital, University of Health Sciences, Etlik, Ankara, Turkey
- ³⁴Unité d'Epidémiologie Clinique, Hôpital Universitaire Robert Debré, APHP, Paris, France
- ³⁵Inserm, CIC-EC 1426, Université Paris Diderot, Paris, France
- ³⁶Service de radiologie, Hôpital Universitaire Robert Debré, APHP, Paris, France
- ³⁷Laboratoire d'Histologie-Embryologie-Cytogénétique-BDR-CECOS, Hôpital Universitaire Jean Verdier APHP, Bondy, France
- ³⁸Institut für Humangenetik, Universität Göttingen, Göttingen, Deutschland
- ³⁹University of Cambridge, Cambridge Institute for Medical Research, Addenbrooke's Hospital, Cambridge, United Kingdom
- ⁴⁰Institute of Medical Genetics, University of Zurich, Schlieren, Zurich, Switzerland
- ⁴¹Center for Developing Brain, King's College, St. Thomas' Campus, London, United Kingdom
- ⁴²Service de Neuropédiatrie, Hôpital Universitaire Robert Debré, APHP, Paris, France

Correspondence

Sandrine Passemard, Inserm U1141, Hôpital Robert Debré, 48 Boulevard Sérurier, 75019, Paris, France.
Email: sandrine.passemard@inserm.fr

Funding information

Agence Nationale de la Recherche, Grant/Award Number: ANR-13-RARE-0007-01; Assistance Publique - Hôpitaux de Paris, Grant/Award Numbers: PHRC, P100128 / IDRCB, 2010, -A01481-38

Contract grant sponsors: The Délégation à la Recherche Clinique et à l'Innovation de l'Assistance Publique Hôpitaux de Paris; The Institut National pour la Santé et la Recherche Médicale (Inserm); The Université Paris 7, DHU PROTECT; National and European Grants (French National Research Agency Programme Hospitalier de Recherche Clinique [PHRC] ERA-NET E-Rare 2013, EuroMicro Project (n° ANR-13-RARE-0007-01).

Communicated by Ravi Savarirayan

Abstract

Autosomal recessive microcephaly or microcephaly primary hereditary (MCPH) is a genetically heterogeneous neurodevelopmental disorder characterized by a reduction in brain volume, indirectly measured by an occipitofrontal circumference (OFC) 2 standard deviations or more below the age- and sex-matched mean ($-2SD$) at birth and $-3SD$ after 6 months, and leading to intellectual disability of variable severity. The abnormal spindle-like microcephaly gene (*ASPM*), the human ortholog of the *Drosophila melanogaster* "abnormal spindle" gene (*asp*), encodes ASPM, a protein localized at the centrosome of apical neuroprogenitor cells and involved in spindle pole positioning during neurogenesis. Loss-of-function mutations in *ASPM* cause MCPH5, which affects the majority of all MCPH patients worldwide. Here, we report 47 unpublished patients from 39 families carrying 28 new *ASPM* mutations, and conduct an exhaustive review of the molecular, clinical, neuroradiological, and neuropsychological features of the 282 families previously reported (with 161 distinct *ASPM* mutations). Furthermore, we show that *ASPM*-related microcephaly is not systematically associated with intellectual deficiency and discuss the association between the structural brain defects (strong reduction in cortical volume and surface area) that modify the cortical map of these patients and their cognitive abilities.

KEYWORDS

ASPM, brain development, brain imaging, centrosome, intellectual disability, MCPH, primary microcephaly

1 | BACKGROUND

Primary microcephaly (PM) refers to a group of autosomal recessive or dominant disorders characterized by a reduction in brain growth starting in utero, intellectual disability (ID) of variable severity, and the absence of extra-CNS malformations (Kaindl et al., 2010; Thornton & Woods, 2009). The worldwide incidence of PM varies from 1:30,000 to 1:250,000 live births, depending on the geographic origin and mode of ascertainment (Komai, Kishimoto, & Ozaki, 1955; Morris et al., 2016; Van Den Bosch, 1959). Microcephaly primary hereditary (MCPH) refers to a subtype of PM in which patients display an isolated

PM with nearly-normal brain cytoarchitecture, originally called "microcephalia vera." Nowadays, MCPH also includes PM with cortical malformations. Clinically, MCPH is defined by an occipitofrontal circumference (OFC) that is 2 standard deviations (SD) or more below the age- and sex-matched mean at birth, and 3 SD or more below the mean after 6 months of age. MCPH might be detected from the 2nd trimester of pregnancy by ultrasound scan (Woods & Parker, 2013).

MCPH is genetically heterogeneous: an MCPH phenotype has been associated with mutations in at least 18 genes, MCPH1-18. Among them, *ASPM* (MCPH5 locus) is the most frequently mutated gene




FIGURE 1 Location of the known and novel mutations identified in the human *ASPM* gene and corresponding domains in the protein. The mutations reported previously are shown on the upper arch. Mutations identified in the present study but already known are indicated by #. Novel mutations from the present study are indicated directly on exons. Various symbols represent missense, nonsense, splice, and frameshift mutations as indicated. Allelic frequency (AF) is indicated if >2%. **Abbreviations:** AF, allelic frequency; ASH, ASPM, SPD-2, Hydin; CH, calponin homology

reported (Verloes, Drunat, Gressens, & Passemard, 2013). Mutations in the remaining 17 genes cause less than 40% of the reported diagnosis. Many MCPH families have not been ascribed to any of the known genes, suggesting that additional MCPH genes are still to be discovered.

The abnormal spindle-like microcephaly gene (*ASPM*; MIM# 605481) is the human ortholog of the *Drosophila melanogaster* “abnormal spindle” gene (*asp*) and maps at the 1q31.3 locus (Bond et al., 2002; Jamieson, Fryns, Jacobs, Matthijs, & Abramowicz, 2000; Pattison et al., 2000). Four isoforms have been described for the *ASPM* gene (Kouprina et al., 2005). The full-length *ASPM* gene contains 28 exons and encodes a 3477 amino-acid protein localized to the spindle pole during metaphase and to the midbody during cytokinesis (Higgins et al., 2010; Kouprina et al., 2005; Paramasivam, Chang, & LoTurco, 2007). *ASPM* plays a crucial role in the division of neural progenitor cells by keeping them cycling, promoting symmetric proliferative divisions at the expense of asymmetric neurogenic divisions (Fish, Kosodo, Enard, Paabo, & Huttner, 2006). Different mouse models in which *Aspm* is knocked out reproduce the microcephaly observed in humans and show a reduction in cortical surface area (Capecchi & Pozner, 2015; Pulvers et al., 2010). The mechanisms underlying *Aspm* microcephaly in mice are an increase in cell cycle duration in neural progenitors, many of which exit the cell cycle, thereby leading to the premature exhaustion of the neural progenitor pool, and a subsequent increase in the production of neurons of the lower cortical layers along with a reduction in upper layer neuron production (Capecchi & Pozner, 2015). Whether these mechanisms also explain microcephaly in humans is still unknown.

The *ASPM* protein (Figure 1) contains an amino-terminal ASH (*ASPM*, *SPD-2*, *Hydin*) domain with a putative microtubule-binding function, found in proteins associated with cilia, flagella, the centrosome, and the Golgi complex (Schou, Morthorst, Christensen, & Pedersen, 2014), an actin binding domain comprising two calponin homology (CH) domains that bind one actin monomer in the filament (Stradal, Kranewitter, Winder, & Gimona, 1998), a series of repeated calmodulin-binding IQ domains, an Armadillo-like domain, and a carboxy-terminal region of unknown significance. Although *ASPM* is highly conserved across species, the variability of its calmodulin-binding IQ repeats is of particular interest. The human protein displays 81 calmodulin-binding IQ repeats at positions 12,73 to 3,234, whereas there are 61 calmodulin-binding IQ repeats in mice and 24 calmodulin-binding IQ repeats in *Drosophila* (Bond et al., 2002; Kouprina et al., 2005; Kouprina et al., 2004). Although still a topic of debate, it has been proposed that the expansion of the cerebral cortex depends on the number of calmodulin-binding IQ repeats (Bond & Woods, 2006; Bond et al., 2002; Kouprina et al., 2005; Kouprina et al., 2004; Ponting & Jackson, 2005).

In vitro experiments have shown that the N-terminal portion of *ASPM*, encoded by the first seven exons, is sufficient to induce *ASPM* localization to the spindle pole during metaphase, whereas the C-terminal domain, encoded by the last three exons, is required for its localization to the midbody during cytokinesis (Kouprina et al., 2005; Paramasivam et al., 2007).

Although a large number of patients with *ASPM* mutations have been reported (Abdel-Hamid et al., 2016b; Ahmad et al., 2016; Akbariazar et al., 2013; Al-Gazali & Ali, 2010; Ariani et al., 2013; Bond

et al., 2002; Bond et al., 2003; Darvish et al., 2010; Desir, Abramowicz, & Tunca, 2006; Desir, Cassart, David, Van Bogaert, & Abramowicz, 2008; Gul et al., 2006; Gul et al., 2007; Halsall, Nicholas, Thornton, Martin, & Geoffrey Woods, 2010; Hashmi et al., 2016; Hu et al., 2014; Kousar et al., 2010; Kumar, Blanton, Babu, Markandaya, & Girimaji, 2004; Muhammad et al., 2009; Nakamura et al., 2015; Nicholas et al., 2009; Papari et al., 2013; Passemard et al., 2009b; Pichon, Vankerckhove, Bourrouillou, Duprez, & Abramowicz, 2004; Rump et al., 2016; Saadi et al., 2009; Sajid Hussain et al., 2013; Shen et al., 2005; Tan et al., 2014; Wang, Khan, Han, & Zhang, 2017), their developmental phenotype has been documented only in a minority of cases. However, ID (Passemard et al., 2009a) and epilepsy (Shen et al., 2005) are the most frequently reported clinical findings in patients with *ASPM* mutations.

In the present review, we report 47 new patients (39 families), followed within the EuroMicro network, and present an exhaustive overview of all individuals with *ASPM* mutations described in the literature since the gene was identified, along with their molecular, clinical, radiological, and neuropsychological features. In particular, this review reveals that microcephaly linked to *ASPM* is not always associated with ID.

2 | MUTATIONS

2.1 | Reported mutations

From the original discovery of *ASPM* mutations (Bond et al., 2002) to July 2017, 161 mutations have been reported. Reports were collected using the PubMed library. The terms “*ASPM*,” “*MCPH5*,” “*MCPH*,” “autosomal recessive microcephaly,” “microcephaly primary hereditary,” and “microcephalic dwarfism” were used as key words. No intragenic copy number variations have been reported in Decipher; only large rearrangements encompassing more than the *ASPM* gene have been reported. The 161 *ASPM* mutations have been identified in 638 affected individuals belonging to 282 families. All the mutations are depicted in Figure 1 and summarized in Supp. Table S1. These mutations are spread all along the coding sequence and include 147 exonic variations, 12 intronic variations, and two large deletions encompassing several exons/introns. Exonic variations ($n = 147$) include 73 nucleotide substitutions (leading to 69 nonsense mutations, two putative splicing mutations, and two missense mutations), 65 deletions of one to few nucleotides (leading to 61 frameshift mutations and four nonsense mutations), and nine duplications or insertions of one nucleotide (leading to frameshift mutations). Intronic variations ($n = 12$) include 10 nucleotide substitutions and two deletions of one nucleotide (all predicted to interfere with correct splicing). Frameshift and splice-site mutations are predicted to result in unstable RNA that would be degraded by nonsense-mediated RNA decay or in truncated protein synthesis. However, few experiments have been carried out to verify this hypothesis except for two mutations located in exon 24 (c.9754del; pArg3252Glufs*10) and in intron 25 (c.9984+1G > T; predicting the removal of the intron 25 splice donor site) (Higgins et al., 2010; Kouprina et al., 2005). In the first case, Western blot analysis has revealed the presence of a truncated protein. In the second

case, although the size and localization of *ASPM* were not affected, only weak expression of the protein was detected at the spindle pole. Among the 161 mutations described so far, three mutations recur frequently. The c.3978G > A mutation (allele frequency = 18%) has been specifically reported in Turkish and Pakistani families (60 families). The c.9557C > G mutation has been reported exclusively in Pakistan (seven families). Both mutations suggest a founder effect. In contrast, the third mutation (c.7782_7783del), which represents 4% of all alleles, is reported in families of different geographic origins (Europe, Africa, and Asia) and is also found in the present study with a high allele frequency (17%). It may therefore correspond to a hotspot mutation.

2.2 | Unreported mutations, methods of identification, cohort

Molecular analysis was performed within our “EuroMicro” European Network (including five partners in France, Belgium, Germany, Switzerland, and the UK), between 2007 and 2017, using samples from patients referred for typical MCPH, PM with cortical malformation or microcephalic primordial dwarfism. The unique inclusion criterion was an OFC lower than 2 SD below the age- and sex-matched mean at birth and lower than 3 SD below the mean after 6 months of age, irrespective of the patient's stature. Exclusion criteria were: (1) a context of anoxia-ischemia at birth, (2) a diagnosis of infectious or toxic fetopathy, or (3) major associated malformations suggestive of syndromic microcephaly.

Mutation analysis was performed on DNA extracted from peripheral blood leucocytes using standard procedures. The coding sequence ± 25 base pairs of intron/exon boundaries of the *ASPM* gene were screened for variants either by Sanger sequencing or next-generation sequencing.

In total, we genotyped 47 patients from 39 unrelated families. Fifteen index cases were born to consanguineous parents. Genotyping identified 18 published and 28 unpublished variants (Table 1 and Figure 1). The new variants included 17 frameshift mutations, nine nonsense mutations, and two splicing mutations, all likely resulting in truncated protein products. Using Alamut Software (Interactive Biosoftware, Rouen, France), the pathogenicity of the identified variants was predicted to result in a loss of *ASPM* function in all cases, even though functional tests are needed to definitively determine their real consequences. Likewise, the presence of additional variants in the genome cannot be ruled out. The molecular data are shown in Table 1 and Figure 1. All mutations have been declared in the Leiden Open Variation Database (databases.lovd.nl/shared/genes/ASPM).

2.3 | Epidemiology and phenotype

2.3.1 | Epidemiology

A total of 685 patients have been reported so far: (47 from the present study + 638 in the literature) from 321 (39 + 282) families. Among those whose sex has been described, 229 (28 + 201) are males and 182 (19 + 163) are females (sex ratio M/F = 1.3). Most families come from

TABLE 1 Novel ASPM mutations identified in our cohort, according to HGVS nomenclature recommendations and using the sequence NM_018136.4 as a reference

Location	DNA HGVS nomenclature	Protein HGVS nomenclature	Protein effect	Families ^a	Origin
Exon 3	c.1850_1853del	p.Thr617Lysfs*30	Frameshift	1	Moroccan
Exon 4	c.1932del	p.Phe645Serfs*23	Frameshift	2	Belgian
Exon 4	c.1943_1944insC	p.Ile649Asnfs*3	Frameshift	3	Moroccan
Exon 9	c.2638G > T	p.Glu880*	Nonsense	4	French
Intron 10	c.2936+2T > C	p.?	Splicing	5	French
Exon 13	c.3185_3189del	p.Asn1062Argfs*28	Frameshift	6	Moroccan
Exon 13	c.3269dup	p.Asp1091*	Nonsense	7	Congolese
Intron 15	c.3741+3A > G	p.?	Splicing	8	African
Exon 18	c.4250_4251del	p.Tyr1417*	Nonsense	9	European
Exon 18	c.4732C > T	p.Arg1578*	Nonsense	10	French
Exon 18	c.4806T > G	p.Tyr1602*	Nonsense	11	Spanish
Exon 18	c.4992_4996dup	p.Arg1667Ilefs*12	Frameshift	12 (n = 2)	Egyptian
Exon 18	c.5590_5591del	p.Leu1864Serfs*2	Frameshift	9	European
Exon 18	c.5886_5887del	p.Leu1963Glu fs*9	Frameshift	13	Cameroonian
Exon 18	c.5940del	p.Tyr1981Ilefs*13	Frameshift	14 (n = 2)	Moroccan
Exon 18	c.6513dup	p.Val2172Serfs*7	Frameshift	15 16	Turkish Turkish
Exon 18	c.6568C > T	p.Gln2190*	Nonsense	4 17 (n = 2)	French French
Exon 18	c.6658C > T	p.Gln2220*	Nonsense	18	Tunisian
Exon 18	c.6919C > T	p.Gln2307*	Nonsense	17 (n = 2)	French
Exon 18	c.6920_6921del	p.Gln2307Leufs*10	Frameshift	19	French
Exon 18	c.7744del	p.Ile2582Serfs*34	Frameshift	20	Italian
Exon 18	c.7753G > T	p.Glu2585*	Nonsense	5	French
Exon 18	c.8599delinsAT	p.Gln2867Ilefs*5	Frameshift	21	French
Exon 18	c.8700_8702delinsCC	p.Lys2900Asnfs*38	Frameshift	22	Moroccan
Exon 18	c.8702del	p.His2901Leufs*37	Frameshift	23 (n = 2) 24 (n = 3)	Egyptian Moroccan
Exon 20	c.9069_9075del	p.His3023Glnfs*2	Frameshift	13	French
Exon 23	c.9446_9447del	p.Arg3149Metfs*17	Frameshift	21	French
Exon 28	c.10369del	p.Glu3457Lysfs*13	Frameshift	8	African

^aFamily number in our series (n = number of sibs).

Patients carrying compound heterozygous mutations are listed twice, once per mutation.

the Asian subcontinent and middle-east: Pakistan (167 families), Saudi Arabia (18), Egypt (2 + 16), and Iran (13); 47 (16 + 31) families are from Europe, and three from the Americas (Figure 2).

2.3.2 | Growth

Although affected patients are described as “microcephalic,” accurate growth parameters (especially OFC) are poorly documented in the literature (reported in less than 3% of patients at birth and only for 26% of patients during childhood). Auxological data for the present study and those reported in the literature are summarized in Figure 3 and include OFC, height, and weight at birth and after 6 years of age. For our European series, SD was calculated according

to Sempé (1979). For cases published previously, we used the SD values provided by the authors. When only absolute values were available, we used WHO Child Growth Standards and WHO Reference 2007.

Microcephaly related to ASPM mutations has exceptionally been reported during pregnancy in two families (Desir et al., 2008; Hu et al., 2014). In the present study, microcephaly was detected during the third trimester of pregnancy in 23 cases (Table 2 and from the second trimester in two cases. However, the impact of these early forms on intellectual prognosis is variable (see details for patients # 8, 9, 13, 20, and 30 in Table 2 and the paragraph on “cognition”).




FIGURE 2 Geographical distribution of families with *ASPM* mutations. The indicated number corresponds to the number of families per country or region. Total number of families = 321 (11 families of unknown origin)




FIGURE 3 OFC, length, and weight measurements in patients with *ASPM* mutations in the present study and in the literature. **A:** OFC and length measurements: Red symbols depict patients from our cohort while black symbols correspond to patients in the literature. Dots represent OFC and lines represent length. Each symbol represents an individual measurement. A single individual may have several measurements at different ages. OFC, occipitofrontal circumference. **B:** OFC, length, and weight averages at birth and after 6 years

Two features characterize the growth of *ASPM*-mutated patients: the reduction of OFC growth kinetics with age and preserved growth in height from birth, as shown in Figure 3.

2.3.3 | Development and clinical features

Walking without support is acquired around 20 months of age (± 11 months, range 10–66 months; data available for $n = 32/42$ in the present study and for $n = 20/605$ in the literature—children aged 18 months or more). 59% walked prior to or at 18 months of age.

Available data related to verbal skills are scarce and heterogeneous in the literature, yet language acquisition seems to be delayed. 17% of patients from the present study were able to make full sentences at 3 years of age (data available for $n = 30/37$ —children aged 3 years or more). Behavioral disorders, such as hyperkinesia, impulsiveness and aggressiveness, were observed in 16 patients from the present study and 17 from the literature. Neurological examination may show pyramidal syndrome or even spasticity ($n = 4$ in the present study and $n = 7$ in the literature). Ataxia and tremors have not been

TABLE 2 Clinical and radiological features of patients of our cohort (39 families, 47 patients)

Ref	Sex	Birth			Last follow up			Walk < 1.5 year	First sentence < 3 years	Epilepsy (if yes, age of onset in years)	Abnormalities in brain MRI, except microcephaly (age in years)	Intellectual assessment Test (age in years): score(s)	Others features
		OFC (in SD)	Length (in SD)	Weight (in SD)	MC on US	Age (in years)	OFC (in SD)	Length (in SD)	Weight (in SD)				
1	M	-7.5	-1	-1.6	T2	11.7	-10	-5.8	-1.3	No	Slight cortical atrophy	NAV	Hyperactivity
2	M	-4.7	0	-0.9	NAv	9.5	-8.9	-0.2	-0.7	Yes	NAv	WPPSI-R (5.8): FSIQ = 64/VIQ = 81/ PIQ = 52	Hyperactivity
3	F	-6.7	-5.2	-3.2	NAv	0.6	-5.8	-1	-1.4	NAp	Gyrat simplification; thin corpus callosum; subcortical hypersignal on T2-weighted images (0.6)	NAp	Hyper-pigmentation spot
4	M	-3.8	-1.5	-0.9	NAv	1.7	-7.5	-2.5	-2.8	No	Gyrat simplification (0.5)	NAp	Behavioral disorders
5	M	-3.4	0	+1.1	No	20	-4.1	-0.8	+0.9	No	NAv	NAv	No
6	F	NA	NA	-1.5	NAv	7	-10.6	-2.2	-2.5	No	Gyrat simplification; corpus callosum hypoplasia (age?)	NAv	Congenital hip dislocation
7	M	-6.6	-2.5	-2.2	NAv	7	-9.5	-0.8	-0.8	Yes (<4)	NAv	NAv	No
8	M	-3.8	-1	-0.8	T3	3.7	-5.6	+1.5	+0.6	No	Ventricular enlargement, cerebellar hypoplasia, subcortical hypersignal on T2-weighted images, elongated superior cerebellar peduncles (3.7)	WPPSI-III (3.7): FSIQ = 60*/VIQ = 74/ PIQ = 54/GCL = 85	No
9	F	-3.8	-1.3	-0.6	T3	4.5	-6.1	+0.5	-0.4	NAv	Gyrat simplification (0.7)	Test? (5y): FSIQ = 50	No
10	F	-4.5	-0.2	-0.7	T3	19	-8.5	-0.2	-0.4	Yes (14)	Gyrat simplification, mild ventricular enlargement; scaphocephaly (0.8)	NAv	Behavioral disorders
11	F	-2.7	-0.5	-1	NAv	3	-3.4	NAv	NAv	No	Gyrat simplification; arachnoid cyst in the posterior fossa; enlarged Virchow-Robin spaces (1.7)	Bayley III (3.5): DQ = 95	No
12.1	F	NAv	NAv	NAv	NAv	7	-7.2	-3.7	-1.9	NAv	Gyrat simplification, mild ventricular enlargement, thin corpus callosum and brainstem (7)	Stanford Binet (7): DQ = 56	No
12.2	M	NAv	NAv	NAv	NAv	0.2	-4.8	+2.5	+0.2	NAp	Gyrat simplification, ventricular and pericerebral space enlargement; thin corpus callosum and brainstem; myelination delay in T2-weighted images (0.3)	NAp	No

(Continues)

TABLE 2 (Continued)

Ref	Sex	Birth			Last follow up			Walk < 1.5 year	First sentence < 3 years	Epilepsy (if yes, age of onset in years)	Abnormalities in brain MRI, except microcephaly (age in years)	Intellectual assessment Test (age in years): score(s)	Others features
		OFC (in SD)	Length (in SD)	Weight (in SD)	MC on US	Age (in years)	OFC (in SD)	Length (in SD)	Weight (in SD)				
13	M	-4.7	-2.5	-2	T3	5.5	-6.4	-0.6	-0.4	No	White matter hypersignal in T2-weighted images, ventricular enlargement (5.5)	WPPSI-III (5.5): FSIQ = 82*/VIQ = 75/ PIQ = 90/GCL = 77	No
14.1	M	NAV	NAV	NAV	T3	9	-8.5	+0.5	NAV	Yes (0.5)	NAV	NAV	Hyperactivity, enuresis
14.2	M	NAV	NAV	NAV	T3	13	-6.5	+1.7	NAV	Yes (0.5)	NAV	NAV	Enuresis
15	F	-4	-1.3	-1.5	No	5.5	-5.5	+0.7	+1.1	No	Gyril simplification, enlarged subarachnoid spaces, mega cisterna magna (0.5)	NAV	No
16	M	-6.5	-1.6	-0.7	T3	NAV	NAV	NAV	NAV	NAV	NAV	NAP	Closed fontanelles before birth
17.1	M	-8.4	-2.6	-4	T3	17.5	-6.9	-1.5	-1.6	No	Slight left cerebral atrophy; cervicothoracic syringomyelia (9)	Borel-Maisonny (4.5): DQ = 56	Spastic hemiplegic cerebral palsy, severe behavioral disorders
17.2	M	-6.6	-2.5	-3.2	T3	17	-7.2	-0.4	-1	No	No (1)	Borel-Maisonny (4.4): DQ = 68	No
18	M	-3.8	-1	+0.2	T2 and T3	1	-6	+2	+1	NAP	No (1)	NAP	Behavioral disorders
19	F	-7.2	-1.1	-0.3	No	3.3	-7	-3	-2.2	No	Gyril simplification, thin corpus callosum, pineal cyst, large arachnoid cyst in the posterior fossa (0.3)	NAV	Left middle ear hypoplasia, behavioral disorders
20	M	-4.3	-0.5	0	T2 and T3	7	-5.6	-1.4	-1.7	Yes (6)	Gyril simplification, polymicrogyria in fronto-insular region (7)	Test? (9.3): DQ = 34	No
21	M	NAV	NAV	NAV	NAV	45	-6.3	NAV	NAV	Yes (7)	Gyril simplification; mild ventricular enlargement; mega cisterna magna; hypersignal of the temporal poles in T2-weighted images; thin brainstem; major vermis and cerebellar atrophy (45)	NAV	Ceroid lipofuscinosis with identified CLN3 mutations (retinitis pigmentosa)
22	F	-2.2	+2	NA	No	15	-4.1	-1.1	+2.3	Yes (15)	No	NAV	No (Continues)

TABLE 2 (Continued)

Ref	Sex	Birth		Last follow up			Walk < 1.5 year	First sentence < 3 years	Epilepsy (if yes, age of onset in years)	Abnormalities in brain MRI, except microcephaly (age in years)	Intellectual assessment Test (age in years); score(s)	Others features
		OFC (in SD)	Length (in SD)	Weight (in SD)	MC on US	Age (in years)	OFC (in SD)	Length (in SD)	Weight (in SD)			
23.1	M	NAV	NAV	NAV	NAV	4	-10.8	-3.9	-3.1	No	NAV	Spastic tetraplegia
23.2	M	NAV	NAV	NAV	NAV	6	-8.4	-1.1	-0.6	NAV	Test? (age?): DQ = 36	Behavioral disorders
24.1	F	NAV	NAV	NAV	No	17	-4.3	-2	-1.2	No	NAV	No
24.2	F	NAV	NAV	NAV	T3	9	-6.2	-1.7	-1.9	No	NAV	No
24.3	M	NAV	NAV	-4.3	T3	7	-8.7	NAV	-2	No	NAV	Vertical nystagmus
25	F	-7.6	NAV	-1.7	T3	0.6	-9.5	-1.2	-2	NAV	NAV	Hypertonia, hyperpigmentation spot
26	M	-7	-4.5	-3	T3	2.7	-10.7	NAV	-1.6	No	NAV	Behavioral disorders, pyramidal syndrome, oral dyspraxia
27	M	-4.7	0	-1.3	No	13	-9.7	-1.6	-1.3	No	NAV	Hypo/hyperpigmentation spots, behavioral disorders
28	F	-2.2	-0.8	+1.5	T3	5	-4.9	-0.3	-0.3	No	NAV	Behavioral disorders
29	M	NAV	NAV	NAV	No	3	-7.6	0	-0.8	No	NAV	Behavioral disorders
30	M	-5.6	-2	-1.8	T3	3.5	-8.8	-1.2	-1.2	No	WPPSI-III (3.5): FSIQ = 55/VIQ = 62/ PIQ = 57/GCL = 65	Hypo/hyperpigmentation spots
31	M	-3.8	-0.5	-0.1	T3	2.3	-6.2	-0.9	-0.2	No	NAV	Hypotonia, behavioral disorders
32.1	F	-4	-1.9	-1.8	No	21.5	-6.2	-1.9	-0.3	No	Test? (12):FSIQ = 70	Scoliosis, hyperpigmentation spot, inverted nipples (Continues)

TABLE 2 (Continued)

Ref	Sex	Birth			Last follow up			Walk < 1.5 year	First sen- tence < 3 years	Epilepsy (if yes, age of onset in years)	Abnormalities in brain MRI, except microcephaly (age in years)	Intellectual assessment Test (age in years): score(s)	Others features
		OFC (in SD)	Length (in SD)	Weight (in SD)	MC on US	Age (in years)	OFC (in SD)	Length (in SD)	Weight (in SD)				
32.2	F	-2.2	-2.4	-0.6	No	23.8	-5.8	-1.1	-0.4	Yes	No	Slight cortical atrophy (1)	Test? (10);FSIQ = 70 Scoliosis, hypopig- mentation spot, inverted nipples
33.1	M	-5.6	-2.5	-2.4	T3	2.7	-7.8	-0.2	-1.1	Yes	No	Gyrals simplification (0.2)	Abnormality of helix
33.2	F	-4.9	-1.9	-0.9	T3	0.2	-5.3	+0.7	-0.4	NAP	NAP	Gyrals simplification; thin corpus callosum (0.2)	Abnormality of helix
34	M	-2.9	-1	-1.1	NAV	11.3	-3.9	+0.3	+0.1	Yes	No	Gyrals simplification; enlarged Virchow-Robin spaces; mega cisterna magna (5)	WPPSI-IV (7.2): FSIQ = 58*/VCI = 86/ FRI = 63/ WMI = 56/ PSI = 66 Behavioral disorders
35	F	-3.1	-0.8	+0.1	T3	1.4	-6.3	-0.4	-1	NAP	No	Gyrals simplification; thin corpus callosum; enlarged Virchow-Robin spaces (0.3)	Behavioral disorders
36	M	-4.3	-1.3	-1.3	NAV	16	-4.3	-3.8	-2.5	Yes	No	Hypersignal of the thalamus in T2-weighted images (13.8)	NAV No
37	F	-4	-0.8	-0.9	No	13	-6.5	-1.5	-1	No	Paroxysmal events	Gyrals simplification, scaphocephaly; enlarged Virchow-Robin spaces, mild enlarged ventricles (11)	NAV Scoliosis
38	M	-5.2	-1.5	-0.8	T3	3.6	-7.3	-1.7	-2.5	Yes	No	Gyrals simplification (fetal)	NAV NAV
39	F	-3.1	-2.2	+0.1	T3	7.4	-7.3	-0.8	-0.5	Yes	No	No (2)	NAV Coarse facial features, retrognathia

For intellectual assessment: DQ, developmental quotient; FSIQ, full-scale intellectual quotient (*if invalidated FSIQ) with VIQ, verbal index quotient; PIQ, performance index quotient, and GCL, general language composite (optional score) in WPPSI-III or WPPSI-R and VCI, verbal comprehension index; FRI, fluid reasoning index; WMI, working memory index; and PSI, processing speed index in WPPSI-IV. VIQ and VCI assess lexical stock, general knowledge, verbal comprehension, and verbal reasoning. PIQ assesses visuospatial skills, abstract categorical reasoning, and non-verbal fluid reasoning abilities (especially assessed by FRI). WMI assesses short-term memory, concentration abilities, cognitive flexibility, and arithmetic reasoning. PSI assesses speed in graphic realization and visual discrimination.

^aFamily number in our series (siblings are indicated as #1.1, 1.2 ...). OFC, occipitofrontal circumference; SD, standard deviation; MC, microcephaly; US, ultrasound; T2, microcephaly detected during 2nd trimester of pregnancy; T3, microcephaly detected during 3rd trimester of pregnancy; NAV, not available; NAP, not applicable.




FIGURE 4 Intellectual abilities of patients with ASPM mutations. **A:** Full-scale IQ of ASPM-mutated patients in the literature and in the present study. Unpaired T-test $*P < 0.05$. **B:** Developmental quotient of ASPM-mutated patients. FSIQ, full-scale intellectual quotient; DQ, developmental quotient

reported. Seizures have been reported in 47 patients (10/47, i.e., 21% in the present study and $n = 37$ in the literature). They appeared during childhood (not before 6 months of age), and were usually sensitive to antiepileptic drugs. Some patients show hypo- and/or hyperpigmented spots (six patients: #3, #25, #27, #30, #32.1, and #32.2). Malformations are rare and do not present a recurrent pattern: scoliosis (two families: patients #32.1, #32.2, and #37), middle ear hypoplasia (one patient: #19), preaxial polydactyly (one patient: (Ahmad et al., 2016)), unilateral cystic kidney (one patient: (Passemar et al., 2009b)), tricuspid insufficiency (one family: (Ariani et al., 2013))), Deafness (one patient (Darvish et al., 2010), Guillain-Barré syndrome (one patient (Passemar et al., 2009b)), and nystagmus (patient #24.3) have been reported or noticed in the present study. Fatal issues have been reported three times in the literature: one patient died after acute myeloid leukemia (Al-Gazali & Ali, 2010) and two children (3 and 9 years old) died without any reported explanation (Abdel-Hamid et al., 2016a; Hashmi et al., 2016). The co-occurrence of two unrelated genetic diseases has been shown in three patients: one with a deletion of the *STS* gene (Abdel-Hamid et al., 2016a), one with oculocutaneous albinism (Abdel-Hamid et al., 2016a), and one with familial retinitis pigmentosa due to *CLN3* mutations (patient #21).

2.3.4 | Cognition

A major prognostic factor to take into account in microcephaly is, naturally, intellectual ability. Although ID, from mild to severe, has been systematically reported in patients with ASPM mutations neuropsychological assessment was performed in only 35/628 patients in the literature (i.e., only 5.6%; Figure 4. Among these 35 patients, a full-scale intellectual quotient (FSIQ) was available for only 24 patients. The mean FSIQ was 54 ± 8 (range 40–71). Despite their ID, we have previously shown that long-term memory in these patients is spared, suggesting that they are able to learn (Passemar et al., 2016).

The remaining 11 were assessed by various motor and language skill assessments, which allowed the developmental quotient (DQ) to be estimated, with a mean value of 46 ± 23 (range 30–104).

In the present study, among 36 children aged of 3 years or more at the last examination, psychological evaluation was not possible for 11 children living outside Europe. Among the remaining families (25 patients), the parents of 14 children agreed to a neuropsychological assessment and their children cooperated. Wechsler tests were first proposed to all patients. These tests are universally accepted tools (translated into many languages) that allow for comparisons between patients from different countries. Six patients were unable to take the Wechsler tests. Therefore, neuropsychologists proposed DQ assessment, using specific tests (Stanford Binet, Borel-Maisonny, Bayley) that are not always internationally available, and only relevant in populations sharing the same language. The mean DQ was 58 ± 15 (range 34–95; Figure 4B and Table 2, similar to scores seen in the literature).

Eight patients were able to perform the different subtests of the Wechsler scales. As shown in Figure 4 and Table 2 the mean FSIQ was 64 ± 10 (range 50–82). As compared with the 24 FSIQ values reported in the literature, the FSIQ of patients in the present study was significantly higher (Figure 4A; $P < 0.05$, un-paired T-test). The “age” factor could explain such a difference. Indeed, our patients are younger (average = 6.6 years) than those described in the literature (average = 11.3 years). These patients may face problems with maintaining their cognitive abilities with time, as tasks become more and more difficult, or may reach the upper limit of their abilities earlier, during childhood or adolescence. The precocity of diagnosis and of appropriate rehabilitation, whose effectiveness also depends on the age factor, would also influence intellectual prognosis. Surprisingly, for four out of five children who underwent detailed neuropsychological assessment (patients #2, 8, 13, and 34; Table 2, at least one subtest, verbal comprehension and/or nonverbal performance, was in the normal range, suggesting learning disabilities rather than ID. For three patients (patients #2, 8, and 34), a difference of 20 points or more between scores was highlighted, leading to a diagnosis of dyspraxia. Furthermore, one child (patient #13; 5.5 years) obtained scores within the normal range or the low average on all subtests and the FSIQ, thus excluding ID (Table 2 and Figure 4. To our knowledge, this is the first report of ASPM-mutated patients with normal intelligence.

2.3.5 | Brain magnetic resonance imaging

Brain magnetic resonance imaging was performed in 39 out of 47 patients from the present study (83%) and has been reported in 50 out of 638 patients (8%) in the literature. The most frequent anomalies were: gyral simplification in 71 out of 89 cases (67% of the present study and 90% of those examined in the literature), corpus callosum abnormalities (shape, size, etc.) in 38 out of 89 cases (31% of the present study and 52% in the literature), and middle to moderate cerebellar and/or pontine hypoplasia in 26 out of 89 cases (15% of the present study [including obvious vermis and cerebellar atrophy in patient #21, who developed a late onset ceroid lipofuscinosis, typically known to induce such atrophy] and 40% in the literature). Such neuroradiological features are often undiscriminating in terms




FIGURE 5 Typical and atypical neuroradiological features of ASPM-related primary microcephaly. **A:** Patient #26 (3 years). **B:** Patient #8 (3.7 years). **C:** Patient #23.1 (4.3 years). **D:** Age-matched control (4 years). From left to right: Sagittal T1-/coronal T1-/axial T1-/coronal T2-weighted images. Drastic reductions in the volume of both hemispheres affecting the white matter and cerebral cortex and gyral simplification are the main features of ASPM-related primary microcephaly (**A**, **B**, and **C**) as compared with age-matched controls. *A contrario*, the volume of the cerebellum is preserved, as shown in the coronal view. Unilateral or bilateral polymicrogyria may be associated with ASPM-related primary microcephaly, as shown in **C** (white arrows)

of diagnosis (Figure 5, since they are not specific either to MCPH or to a specific type of MCPH. Some atypical features have also been described: polymicrogyria in three cases (patient #23.1 with extensive bilateral posterior polymicrogyria and (Marchal et al., 2011; Passemard et al., 2009b)), and syringomyelia (patient #17.1). Conventional imaging is thus not informative enough to orient diagnosis or to predict prognosis, except if it shows migration disorders associated with microcephaly, such as polymicrogyria, that may increase the risk of epilepsy. The reduction of brain volume in humans provides evidence for early neuronal and glial defects. The existence of polymicrogyria shows that migration disorders are associated with proliferation defects in ASPM microcephaly.

2.4 | Genotype–phenotype correlation

The vast majority of ASPM mutations are nonsense or frameshift mutations, predictive of the synthesis of a truncated protein. No IQ is available for patients carrying the two missense mutations (Ahmad et al., 2016; Darvish et al., 2010; Gul et al., 2006; Kraemer 2016). Most ASPM mutations are private. Moreover, intra-familial variability is frequent. In our opinion, the available data are still too scarce to make any correlations, underlining the need for better characterization of this rare disease.

3 | FUTURE PROSPECTS

Major efforts have been made for the molecular diagnosis of MCPH, and the implementation of NGS in clinical diagnosis has identified ASPM mutations as the principal cause of MCPH worldwide. Although the vast majority of ASPM mutations likely result in the loss of function of the protein product, systematic functional studies are still required to prove the pathogenicity of the variants, and not only refine our knowledge of the roles of this protein but determine whether all mutations have the same consequences or whether some have differential impacts on the cell. The high number of patients reported is also countered by the drastic lack of fine clinical descriptions, neurocognitive investigations, and large-scale studies correlating anomalies of brain morphology with neurodevelopmental, cognitive, and behavioral characteristics. Hence, we have only limited knowledge regarding the real intellectual abilities and their natural history in these patients, or their functional cortical organization and cortical maps. To obtain new insights into ASPM-specific brain defects, two different approaches to cortical structure should be considered: structural brain imaging and the neuropathological study of post mortem cases. Indeed, we have shown that the 50% average reduction in brain volume is caused by a major reduction of cortical gray and white matter volumes that are in contrast to the relative preservation of the volume of the brainstem

and cerebellum (Passemar et al., 2016). This massive reduction in cortical volume and cortical surface preferentially affects the neocortex and spares the hippocampus and mesiotemporal cortices, involved in long-term memory tasks, concordant with the preserved mnemonic functions of these patients (Passemar et al., 2016). The autonomy and social insertion of these patients as adults as well as genetic counseling for their families would benefit from improved knowledge of the structural and cognitive characteristics of the brain.

Many biological questions remain regarding the mechanisms underlying ASPM-microcephaly in humans. Mouse models have confirmed that the *Aspm* gene plays a major role in cortical expansion, promoting the symmetric proliferative divisions of neural progenitors. It is now crucial to better understand the consequences of ASPM mutations, not only in terms of neuronal production in affected patients, but also in terms of the specification/differentiation of these neurons, their connectivity and obviously their function. Improving synaptic plasticity in these patients to enhance their cognitive abilities is a future scientific challenge.

ACKNOWLEDGMENT

We are grateful to Dr. Sowmyalakshmi Rasika for relevant comments and language editing during the preparation of this manuscript.

DISCLOSURE STATEMENT

The authors declare no conflict of interest.

ORCID

Sandrine Passemar  <http://orcid.org/0000-0002-0242-4566>

REFERENCES

- Abdel-Hamid, M. S., Ismail, M. F., Darwish, H. A., Effat, L. K., Zaki, M. S., & Abdel-Salam, G. M. (2016a). Co-occurrence of primary microcephaly caused by a novel homozygous *Aspm* mutation along with X-linked ichthyosis in the same patient. *Genetic Counseling*, 27(1), 25–33.
- Abdel-Hamid, M. S., Ismail, M. F., Darwish, H. A., Effat, L. K., Zaki, M. S., & Abdel-Salam, G. M. (2016b). Molecular and phenotypic spectrum of ASPM-related primary microcephaly: Identification of eight novel mutations. *American Journal of Medical Genetics A*, 170(8), 2133–2140.
- Ahmad, I., Baig, S. M., Abdulkareem, A. R., Hussain, M. S., Sur, I., Toliat, M. R., ... Nürnberg, P. (2016). Genetic heterogeneity in Pakistani microcephaly families revisited. *Clinical Genetics*, 92(1), 62–68.
- Akbariazar, E., Ebrahimpour, M., Akbari, S., Arzhanghi, S., Abedini, S. S., Najmabadi, H., ... Kahrizi, K. (2013). A novel deletion mutation in ASPM gene in an Iranian family with autosomal recessive primary microcephaly. *Iranian Journal of Child Neurology*, 7(2), 23–30.
- Al-Gazali, L., & Ali, B. R. (2010). Mutations of a country: A mutation review of single gene disorders in the United Arab Emirates (UAE). *Human Mutations*, 31(5), 505–520.
- Ariani, F., Mari, F., Amitrano, S., Di Marco, C., Artuso, R., Scala, E., ... Renieri, A. (2013). Exome sequencing overrides formal genetics: ASPM mutations in a case study of apparent X-linked microcephalic intellectual deficit. *Clinical Genetics*, 83(3), 288–290.
- Bond, J., Roberts, E., Mochida, G. H., Hampshire, D. J., Scott, S., Askham, J. M., ... Woods, C. G. (2002). ASPM is a major determinant of cerebral cortical size. *Nature Genetics*, 32(2), 316–320.
- Bond, J., Scott, S., Hampshire, D. J., Springell, K., Corry, P., Abramowicz, M. J., ... Woods, C. G. (2003). Protein-truncating mutations in ASPM cause variable reduction in brain size. *American Journal of Human Genetics*, 73(5), 1170–1177.
- Bond, J., & Woods, C. G. (2006). Cytoskeletal genes regulating brain size. *Current Opinion in Cell Biology*, 18(1), 95–101.
- Capecchi, M. R., & Pozner, A. (2015). ASPM regulates symmetric stem cell division by tuning Cyclin E ubiquitination. *Nature Communication*, 6, 8763.
- Darwish, H., Esmaeeli-Nieh, S., Monajemi, G. B., Mohseni, M., Ghasemi-Firouzabadi, S., Abedini, S. S., ... Najmabadi, H. (2010). A clinical and molecular genetic study of 112 Iranian families with primary microcephaly. *Journal of Medical Genetics*, 47(12), 823–828.
- Desir, J., Abramowicz, M., & Tunca, Y. (2006). Novel mutations in prenatal diagnosis of primary microcephaly. *Prenatal Diagnosis*, 26(10), 989.
- Desir, J., Cassart, M., David, P., Van Bogaert, P., & Abramowicz, M. (2008). Primary microcephaly with ASPM mutation shows simplified cortical gyration with antero-posterior gradient pre- and post-natally. *American Journal of Medical Genetics A*, 146A(11), 1439–1443.
- Fish, J. L., Kosodo, Y., Enard, W., Paabo, S., & Huttner, W. B. (2006). *Aspm* specifically maintains symmetric proliferative divisions of neuroepithelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, 103(27), 10438–10443.
- Gul, A., Hassan, M. J., Mahmood, S., Chen, W., Rahmani, S., Naseer, M. I., ... Ahmad, W. (2006). Genetic studies of autosomal recessive primary microcephaly in 33 Pakistani families: Novel sequence variants in ASPM gene. *Neurogenetics*, 7(2), 105–110.
- Gul, A., Tariq, M., Khan, M. N., Hassan, M. J., Ali, G., & Ahmad, W. (2007). Novel protein-truncating mutations in the ASPM gene in families with autosomal recessive primary microcephaly. *Journal of Neurogenetics*, 21(3), 153–163.
- Halsall, S., Nicholas, A. K., Thornton, G., Martin, H., & Geoffrey Woods, C. (2010). Critical consequences of finding three pathogenic mutations in an individual with recessive disease. *Journal of Medical Genetics*, 47(11), 769–770.
- Hashmi, J. A., Al-Harbi, K. M., Ramzan, K., Albalawi, A. M., Mehmood, A., Samman, M. I., & Basit, S. (2016). A novel splice-site mutation in the ASPM gene underlies autosomal recessive primary microcephaly. *Annals of Saudi Medicine*, 36(6), 391–396.
- Higgins, J., Midgley, C., Bergh, A. M., Bell, S. M., Askham, J. M., Roberts, E., ... Bond, J. (2010). Human ASPM participates in spindle organisation, spindle orientation and cytokinesis. *BMC Cell Biology*, 11, 85.
- Hu, H., Suckow, V., Musante, L., Roggenkamp, V., Kraemer, N., Ropers, H. H., ... Kaindl, A. M. (2014). Previously reported new type of autosomal recessive primary microcephaly is caused by compound heterozygous ASPM gene mutations. *Cell Cycle*, 13(10), 1650–1651.
- Jamieson, C. R., Fryns, J. P., Jacobs, J., Matthijs, G., & Abramowicz, M. J. (2000). Primary autosomal recessive microcephaly: MCPH5 maps to 1q25-q32. *American Journal of Human Genetics*, 67(6), 1575–1577.
- Kaindl, A. M., Passemar, S., Kumar, P., Kraemer, N., Issa, L., Zwierner, A. et al. (2010). Many roads lead to primary autosomal recessive microcephaly. *Progress in Neurobiology*, 90(3), 363–383.
- Komai, T., Kishimoto, K., & Ozaki, Y. (1955). Genetic study of microcephaly based on Japanese material. *American Journal of Human Genetics*, 7(1), 51–65.
- Kouprina, N., Pavlicek, A., Collins, N. K., Nakano, M., Noskov, V. N., Ohzeki, J., ... Larionov, V. (2005). The microcephaly ASPM gene is expressed in proliferating tissues and encodes for a mitotic spindle protein. *Human Molecular Genetics*, 14(15), 2155–2165.

- Kouprina, N., Pavlicek, A., Mochida, G. H., Solomon, G., Gersch, W., Yoon, Y. H., ... Larionov, V. (2004). Accelerated evolution of the ASPM gene controlling brain size begins prior to human brain expansion. *PLoS Biology*, 2(5), 653–663.
- Kousar, R., Nawaz, H., Khurshid, M., Ali, G., Khan, S. U., Mir, H., ... Ansar, M. (2010). Mutation analysis of the ASPM gene in 18 Pakistani families with autosomal recessive primary microcephaly. *J Child Neurol*, 25(6), 715–720.
- Kumar, A., Blanton, S. H., Babu, M., Markandaya, M., & Girimaji, S. C. (2004). Genetic analysis of primary microcephaly in Indian families: Novel ASPM mutations. *Clinical Genetics*, 66(4), 341–348.
- Marchal, J. A., Ghani, M., Schindler, D., Gavvovidis, I., Winkler, T., Esquitino, V., ... Neitzel, H. (2011). Misregulation of mitotic chromosome segregation in a new type of autosomal recessive primary microcephaly. *Cell Cycle*, 10(17), 2967–2977.
- Morris, J. K., Rankin, J., Garne, E., Loane, M., Greenlees, R., Addor, M. C., ... Dolk, H. (2016). Prevalence of microcephaly in Europe: Population based study. *BMJ*, 354, i4721.
- Muhammad, F., Mahmood Baig, S., Hansen, L., Sajid Hussain, M., Anjum Inayat, I., Aslam, M., ... Kjaer, K. W. (2009). Compound heterozygous ASPM mutations in Pakistani MCPH families. *American Journal of Medical Genetics A*, 149A(5), 926–930.
- Nakamura, K., Inui, T., Miya, F., Kanemura, Y., Okamoto, N., Saitoh, S., ... Kato, M. (2015). Primary microcephaly with anterior predominant pachygyria caused by novel compound heterozygous mutations in ASPM. *Pediatric Neurology*, 52(5), e7–8.
- Nicholas, A. K., Swanson, E. A., Cox, J. J., Karbani, G., Malik, S., Springell, K. et al. (2009). The molecular landscape of ASPM mutations in primary microcephaly. *Journal of Medical Genetics*, 46(4), 249–253.
- Papari, E., Bastami, M., Farhadi, A., Abedini, S. S., Hosseini, M., Bahman, I., ... Najmabadi, H. (2013). Investigation of primary microcephaly in Bushehr province of Iran: Novel STIL and ASPM mutations. *Clinical Genetics*, 83(5), 488–490.
- Paramasivam, M., Chang, Y. J., & LoTurco, J. J. (2007). ASPM and citron kinase co-localize to the midbody ring during cytokinesis. *Cell Cycle*, 6(13), 1605–1612.
- Passemard, S., Kaindl, A. M., Titomanlio, L., Gerard, B., Gressens, P., & Verloes, A. (2009a). Primary autosomal recessive microcephaly. *GeneReviews at GeneTests. Medical Genetics Information Resource* [database online]. Copyright: University of Washington, 1997–2009. Available at Retrieved from <https://www.genetests.org>
- Passemard, S., Titomanlio, L., Elmaleh, M., Afenjar, A., Alessandri, J. L., Andria, G., ... Verloes, A. (2009b). Expanding the clinical and neuroradiologic phenotype of primary microcephaly due to ASPM mutations. *Neurology*, 73(12), 962–969.
- Passemard, S., Verloes, A., Billette de Villemeur, T., Boespflug-Tanguy, O., Hernandez, K., Laurent, M., ... Schaer, M. (2016). Abnormal spindle-like microcephaly-associated (ASPM) mutations strongly disrupt neocortical structure but spare the hippocampus and long-term memory. *Cortex*, 74, 158–176.
- Pattison, L., Crow, Y. J., Deeble, V. J., Jackson, A. P., Jafri, H., Rashid, Y., ... Woods, C. G. (2000). A fifth locus for primary autosomal recessive microcephaly maps to chromosome 1q31. *American Journal of Human Genetics*, 67(6), 1578–1580.
- Pichon, B., Vankerckhove, S., Bourrouillou, G., Duprez, L., & Abramowicz, M. J. (2004). A translocation breakpoint disrupts the ASPM gene in a patient with primary microcephaly. *European Journal of Human Genetics*, 12(5), 419–421.
- Ponting, C., & Jackson, A. P. (2005). Evolution of primary microcephaly genes and the enlargement of primate brains. *Current Opinion in Genetics and Development*, 15(3), 241–248.
- Pulvers, J. N., Bryk, J., Fish, J. L., Wilsch-Brauninger, M., Arai, Y., Schreier, D., ... Huttner, W. B. (2010). Mutations in mouse *Aspm* (abnormal spindle-like microcephaly associated) cause not only microcephaly but also major defects in the germline. *Proceedings of the National Academy of Sciences of the United States of America*, 107(38), 16595–16600.
- Rump, P., Jazayeri, O., van Dijk-Bos, K. K., Johansson, L. F., van Essen, A. J., Verheij, J. B., ... Sikkema-Raddatz, B. (2016). Whole-exome sequencing is a powerful approach for establishing the etiological diagnosis in patients with intellectual disability and microcephaly. *BMC Medical Genomics*, 9, 7.
- Saadi, A., Borck, G., Boddaert, N., Chekkour, M. C., Imessaoudene, B., Munnich, A., ... Chaouch, M. (2009). Compound heterozygous ASPM mutations associated with microcephaly and simplified cortical gyration in a consanguineous Algerian family. *European Journal of Medical Genetics*, 52(4), 180–184.
- Sajid Hussain, M., Marriam Bakhtiar, S., Farooq, M., Anjum, I., Janzen, E., Reza Toliat, M., ... Hansen, L. (2013). Genetic heterogeneity in Pakistani microcephaly families. *Clinical Genetics*, 83(5), 446–451.
- Schou, K. B., Morthorst, S. K., Christensen, S. T., & Pedersen, L. B. (2014). Identification of conserved, centrosome-targeting ASH domains in TRAPP1 complex subunits and TRAPPC8. *Cilia*, 3, 6.
- Sempé, M. P. G., & Roy-Pernot, M. P. (1979). *Auxologie-méthodes et séquences*. Paris: Theraplix.
- Shen, J., Eyaid, W., Mochida, G. H., Al-Moayyad, F., Bodell, A., Woods, C. G., ... Walsh, C. A. (2005). ASPM mutations identified in patients with primary microcephaly and seizures. *Journal of Medical Genetics*, 42(9), 725–729.
- Stradal, T., Kranewitter, W., Winder, S. J., & Gimona, M. (1998). CH domains revisited. *FEBS Letters*, 431(2), 134–137.
- Tan, C. A., del Gaudio, D., Dempsey, M. A., Arndt, K., Botes, S., Reeder, A., ... Das, S. (2014). Analysis of ASPM in an ethnically diverse cohort of 400 patient samples: Perspectives of the molecular diagnostic laboratory. *Clinical Genetics*, 85(4), 353–358.
- Thornton, G. K., & Woods, C. G. (2009). Primary microcephaly: Do all roads lead to Rome? *Trends in Genetics*, 25(11), 501–510.
- Van Den Bosch, J. (1959). Microcephaly in the Netherlands: A clinical and genetical study. *Annals of Human Genetics*, 23(2), 91–116.
- Verloes, A., Drunat, S., Gressens, P., & Passemard, S. (2013). Primary autosomal recessive microcephalies and Seckel syndrome spectrum disorders. In M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, H. C. Mefford, K. Stephens, A. Amemiya, N. Ledbetter (Eds.), *GeneReviews*®. Seattle (WA): University of Washington, Seattle; 1993–2017.
- Wang, R., Khan, A., Han, S., & Zhang, X. (2017). Molecular analysis of 23 Pakistani families with autosomal recessive primary microcephaly using targeted next-generation sequencing. *Journal of Human Genetics*, 62(2), 299–304.
- Woods, C. G., & Parker, A. (2013). Investigating microcephaly. *Archives of Disease in Childhood*, 98(9), 707–713.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Létard P, Drunat S, Vial Y, et al. Autosomal recessive primary microcephaly due to ASPM mutations: an update. *Human Mutation*. 2018;39:319–332. <https://doi.org/10.1002/humu.23381>